Raya Therapeutic's smilagenin has been selected for EXPERTS-ALS. Read how this new drug could accelerate the search for MND treatments.

The Annual Stephen Hawking MND Lectures were launched 2017 – and are now and established and important part of the Association’s calendar.

A new study reveals what people with MND need when deciding on genetic testing, including clear information and tailored support.

Covid-19 Boosters in the UK – Statement This autumn is the first since the Joint Committee on Vaccination and Immunisation (JCVI) changed its policy on who can receive Covid-19 vaccination bo…

Discover how repurposed drugs are helping accelerate the search for effective treatments for MND through innovative UK research.

Former England captain Lewis Moody reveals he has been diagnosed with motor neurone disease in an exclusive BBC interview.

Plasma proteomic analysis of presymptomatic individuals with amyotrophic lateral sclerosis identifies novel disease-associated proteins and enables the development of an accurate diagnostic biomarker ...

A new international challenge prize has been launched to transform drug discovery for ALS, the most common form of MND through AI.

Postdoc Research Assistant in Dr Arpan Mehta’s lab at University of Dundee, using CRISPR screens in iPSC-derived motor neurons to study ALS mechanisms.

Mike Rogers, MND Association Director of Research and Innovation, looks at how data and AI could unlock new treatments.

Research has found that disrupted sleep may offer some clues to possible early warning signs of the ALS or FTD.

Disruption of the 3D genome caused by structural variation contributes to developmental disorders and cancer. The authors review the causes and molecular and clinical consequences of position effects arising from disruptions to the genome architecture.

Research Fellow vacancy at UCL MND Centre. Join Prof Andrea Malaspina’s team to study immune responses & neoantigens in ALS using proteomics & cell phenotyping

One in 300 of us will develop motor neurone disease in our lifetime. It is a hideous disease that robs a person of their dignity and eventually their life.

Apply for the NIHR Senior Investigator award: £15K per year for 4 years to support leading applied research and shape the future of health and social care.

What an incredible week! Thank you to everyone who helped make the launch of the #LongitudePrizeOnALS such a success — from the inspiring voices on stage, to the teams that made this Prize possible, ...

Join Dr Arpan Mehta's lab at MRC PPU, University of Dundee, for a 12-month postdoc using CRISPR screens to explore ALS in iPSC-derived motor neurons.

On MND Awareness Day, we’re spotlighting the projects accelerating real progress and explaining why translational research is key.

Sir Simon Wessely, Professor of Psychological Medicine at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has been awarded the honour for services to mental hea...

Join a leading dementia research team as a Clinical Research Fellow at UCL. Work on trials for novel Alzheimer’s and FTD therapies.

Read about some of our latest findings from the MND Register that were showcased at the ENCALS Meeting 2025 in Turin, Italy.

Researchers at Washington University in St. Louis and St. Jude Children’s Research Hospital have found that biomolecular condensates play a role in suppressing the effects of ALS-causing mutations.

International Conference, in partnership with the UK MND Research Institute, on ALS / MND - TRANSLATING TARGETS TO THERAPIES

The new MND Register website helps track MND across the UK and support research into who is affected, how, and why. Visit to learn more.

Abstract. SNP heritability (h2snp) is defined as the proportion of phenotypic variance explained by genotyped SNPs and is believed to be a lower bound of h

The UK MND Clinical Studies Group has released a statement regarding the MIROCALS clinical trial results, recently published in The Lancet.

The UK MND Clinical Studies Group has released a statement regarding the MIROCALS clinical trial results, recently published in The Lancet.

Results of the landmark MIROCALS clinical trial, involving researchers from the University of Sheffield, have revealed new insights into the treatment of motor neuron disease (MND).